# Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct00576914/  
OnCo record `nct00576914` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Recombinant human endostatin in Non-small-cell lung cancer, run by Chinese Academy of Sciences, with a status the registry has not verified recently.

## Summary

Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT00576914 by Chinese Academy of Sciences, with 1108 participants planned, started 2007-06 and due to reach its primary completion in 2012-06. Interventions recorded: recombinant human endostatin. Conditions recorded: Non-small Cell Lung Cancer.

Linked to the drug Recombinant human endostatin because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00576914
- Phase: 3
- Setting: Adjuvant Vinorelbine Plus Cisplatin Versus Vinorelbine Plus Cisplatin Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer (Phase III Study, Randomized, Open, Multi-center)
- Sponsor: Chinese Academy of Sciences
- Enrolled: 1108

## Sources

- ClinicalTrials.gov NCT00576914: https://clinicaltrials.gov/study/NCT00576914

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Recombinant human endostatin](https://onco.cc/drugs/recombinant-human-endostatin/)

---
JSON: https://onco.cc/api/v1/entities/nct00576914.json